Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06484335 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV

Study acronym: ACHIEV
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 11 months later Aug 1, 2027 → Jul 17, 2029
See other at-risk trials from Henry M. Jackson Foundation for the Advancement of Military Medicine

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Aug 1, 2027 to Jul 17, 2029
    • Eligibility criteria expanded, about 28 words
    v5
  2. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v4
  3. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Start date changed from estimate of May 1, 2025 to Mar 27, 2025
    • Site contact updated
    v3
  4. Start date: Feb 1, 2025 to May 1, 2025
    • Secondary endpoints: 19 to 16
    • Study description expanded, about 61 words
    • Study title shortened, about 5 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase I, randomized, double-blind, placebo-controlled clinical trial to investigate the safety of VRC07-523LS and PGDM1400LS in combination with ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62 prime, MVA.tHIVconsv4 and A244d11gp120/ALFQ vaccination, and the impact on viral load setpoint during analytic treatment interruption (ATI) in people living with human immunodeficiency virus-1 (HIV-1, PLWH) who have initiated or will initiate antiretroviral therapy (ART) during acute HIV-1 infection (AHI).
Trial Details
NCT Number NCT06484335
Lead Sponsor Henry M. Jackson Foundation for the Advancement of Military Medicine
Collaborators: US Military HIV Research Program
Conditions
(from sponsor)		 HIV Infections, PLWH, ART, Acute HIV Infection
Related terms HIV Infections
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov